BillionaireNet
Baker
F
Rank #1463
UNITED STATESFinance & InvestmentsBiotech investing

Felix Baker

Net Worth
$2.756B
0% (24h)
Felix Baker is a prominent figure in the biotech investment world, co-founding Baker Bros. Advisors. His expertise in biotech investing has led to a net worth of $2.8 billion as of December 2025. He is 56 years old and has a background in immunology. His career highlights his success in the financial industry through strategic investments in the biotech sector. He manages long-term investment funds for major endowments and foundations.

The Full Dossier

Early Life and Education

Felix Baker was born in March 1969. He graduated from Stanford University with a B.S. in Biology in 1991 and a Ph.D. in immunology in 1998, he also completed two years of medical school. His academic background in immunology laid a solid foundation for his future ventures.

Rise to Success

In 2000, Felix Baker co-founded Baker Bros. Advisors with his brother, Julian Baker. The firm specializes in biotechnology stocks and has become a leading biotech investor. Baker's firm was managing about $23 billion in assets as of March 2023. The two brothers started their fund-management careers in 1994 with a biotechnology investing partnership with the Tisch Family.

Key Business Strategies

Baker's investment strategy focuses heavily on the biotechnology sector. The firm's success is attributed to strategic investments in major biotech entities. Baker Bros. Advisors employs a fundamentally driven, long-term investment approach, concentrating capital in a select group of high-conviction investments.

Philanthropy

While specific figures are difficult to ascertain, Baker is known to be involved in philanthropy, particularly through his involvement in Stanford's bioscience initiatives, and supporting the development of drugs to treat unmet medical needs.

Career Timeline

2024

Lead Independent Director

Serves as Lead Independent Director at Kymera Therapeutics, Inc.

2017

Appointed to Stanford Board of Trustees

Involved in Stanford's interdisciplinary sciences programs.

2015-2021

Board Member

Served on the board of Alexion Pharmaceuticals, Inc.

2003-2023

Board Member

Served on the board of Seagen, Inc.

2000

Co-founded Baker Bros. Advisors

Launched a hedge fund specializing in biotechnology stocks.

1994

Began Fund Management Career

Started a biotechnology investment partnership with the Tisch Family.

Philanthropic Impact

EducationUndisclosed

Stanford Biosciences Initiatives

Involved with Stanford's interdisciplinary sciences programs.

Wealth Trajectory